KLK3 and posterior cortical atrophy: In addition to PSA, other serum and urinary biomarkers (reviewed in [1]) have been identified and approved by the Food and Drug Administration (FDA) and Clinical Laboratory Improvement Amendments (CLIA) for improving PCa diagnosis and prognosis, and helping in biopsy decision.